Loading...

Shenzhen Neptunus Interlong Bio-technique Company Limited

8329.HK•HKSE
Healthcare
Drug Manufacturers - Specialty & Generic
HK$0.16
HK$-0.00(-2.44%)
empty-state-iconFinancials data is not available for this stockFinancials details for this stock are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Over the last four quarters, Shenzhen Neptunus Interlong Bio-technique Company Limited's revenue moved from $267.65M in Q3 2023 to $264.18M in Q2 2024. Operating income in Q2 2024 was $24.79M, with a strong operating margin of 9%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Shenzhen Neptunus Interlong Bio-technique Company Limited remained robust at $30.31M, reflecting operational efficiency. Net income dropped to $18.61M, with an EPS of $0.01. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;